301520 万邦医药
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)0.0092.4065.74512.03934.981
总资产报酬率 ROA (%)0.0082.2735.43311.09128.692
投入资产回报率 ROIC (%)0.0092.3605.64011.71232.523

边际利润分析
销售毛利率 (%)18.39825.89939.57948.93850.382
营业利润率 (%)-3.58715.12322.96034.81740.679
息税前利润/营业总收入 (%)-3.95412.71222.77833.65442.280
净利润/营业总收入 (%)0.15713.28922.56231.62437.861

收益指标分析
经营活动净收益/利润总额(%)531.52125.20666.12392.77088.699
价值变动净收益/利润总额(%)-485.07189.02331.4985.1982.857
营业外收支净额/利润总额(%)2.363-15.6542.7450.5344.555

偿债能力分析
流动比率 (X)4.99320.78518.77420.3514.387
速动比率 (X)4.98820.77218.74820.3414.380
资产负债率 (%)15.9245.4375.6395.21718.038
带息债务/全部投入资本 (%)5.4170.5940.7970.9464.158
股东权益/带息债务 (%)1,720.92616,504.50312,317.59710,378.5712,252.206
股东权益/负债合计 (%)516.7561,739.2301,673.3491,816.848454.373
利息保障倍数 (X)14.105-34.845-27.427-24.926-123.982

营运能力分析
应收账款周转天数 (天)181.70395.33555.51445.53033.319
存货周转天数 (天)2.8742.5092.0641.1450.868